JMJia-Wei Mei

Jia-Wei Mei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jia-Wei Mei has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Li-Jia Pan

    Department of General Surgery, Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Yi-Jun Shu

    Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Cheng Zhao

    Laboratory of General Surgery and Department of General Surgery, Xinhua Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092, China; Shanghai Key Laboratory of Biliary Tract Disease Research, No. 1665 Kongjiang Road, Shanghai 200092, China

    1 shared publication
  • Hao Weng

    Department of General Surgery, Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Honggang Xiang

    Department of General Surgery Pudong New Area People's Hospital Shanghai China

    1 shared publication
  • Jian Zhang

    Laboratory of General Surgery and Department of General Surgery, Xinhua Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai 200092, China; Shanghai Key Laboratory of Biliary Tract Disease Research, No. 1665 Kongjiang Road, Shanghai 200092, China

    1 shared publication

Latest Publications

  • Open Access

    Outcomes after therapeutic SBE-ERCP for choledochojejunal/hepaticojejunal anastomotic stenosis after bile duct injury

    by Yijun Shu, Pak-Lam Koo, Hao Weng, Li-Jia Pan, Ming-Zhe Weng, Ziyi Yang, Ming-Ning Zhao, Wen-Jie Zhang, Jun Gu, Wei Gong, et al.

    Background: Choledochojejunal/hepaticojejunal anastomotic stenosis (CJS/HJS) is significant clinical problem associated with decreased survival postsurgery. Endoscopic retrograde cholangiopancreatography (ERCP) using single-balloon enteroscopy (SBE) is the first-line management strategy for such conditions. However, studies on the risk factors and outcomes of endoscopic management strategies for CJS/HJS in biliary duct injury (BDI) are extremely limited. Methods: We conducted a retrospective review of patients with symptomatic BDI who underwent choledochojejunal/hepaticojejunal Roux-en-Y anastomosis between April 2009 and April 2019. The primary endpoint was CJS/HJS recurrence. The secondary endpoint was early (i.e., emergent or unplanned) repeat SBE-ERCP (ER-SBE-ERCP). We also evaluated the details of initial therapy, complications, and treatment for CJS or HJS recurrence. Results: From April 2009 to April 2019, 112 patients were treated, and 45 (40.2%) BDI patients developed CJS/HJS. Operation type ( P < 0.001), salvage surgery timing ( P = 0.005), hepatic artery injury ( P = 0.001), bile leakage after surgery ( P < 0.001) and recurrent cholangitis ( P < 0.001) were significantly associated with anastomotic stenosis. The overall CJS/HJS recurrence rate was 27.9% (12/43). Of all the patients, 79.1% (34/43) underwent balloon dilation at the anastomotic stenosis site; stent placement was performed in 33 of 43 patients (76.8%). The complication rate was 7% (3/43).Initial balloon dilation ( P = 0.024) was associated with the proportion of patients requiring ER-SBE-ERCP. Predictors of CJS/HJS recurrence on bivariate analysis included initial balloon dilation ( P < 0.001) and ER-SBE-ERCP ( P < 0.001). On multivariate analysis, ER-SBE-ERCP was significantly associated with CJS/HJS recurrence, likely reflecting the presence of more severe lesions or higher baseline risks for recurrence, rather than being a direct cause of recurrence. Conclusions: Initial balloon dilation is associated with a decreased risk of CJS/HJS recurrence. ER-SBE-ERCP is more commonly performed in patients with severe anastomotic lesions or higher baseline risks for recurrence, which may contribute to the higher observed recurrence rates of CJS/HJS in this group.

  • Open Access

    Ponicidin inhibited gallbladder cancer proliferation and metastasis by decreasing MAGEB2 expression through FOXO4

    by Cheng Zhao, Jian Zhang, Zi-Yi Yang, Liu-Qing Shi, Shi-Lei Liu, Li-Jia Pan, Ping Dong, Yi Zhang, Shan-Shan Xiang, Yi-Jun Shu, et al.


  • Open Access

    MicroRNA-1275 inhibits cell migration and invasion in gastric cancer by regulating vimentin and E-cadherin via JAZF1

    by Jia-Wei Mei, Zi-Yi Yang, Hong-Gang Xiang, Runfa Bao, Yuan-Yuan Ye, Tai Ren, Xue-Feng Wang, Yi-Jun Shu

    Emerging evidence has shown that miR-1275 plays a critical role in tumour metastasis and the progression of various types of cancer. In this study, we analysed the role and mechanism of miR-1275 in the progression and prognosis of gastric cancer (GC). Target genes of miR-1275 were identified and verified by luciferase assay and Western blotting. The function of miR-1275 in invasion and metastasis was analysed in vitro and in vivo in nude mice. The signal pathway regulated by miR-1275 was examined by qRT-PCR, Western blotting and chromatin immunoprecipitation analyses. The expression of miR-1275and JAZF1 were measured in specimens of GC and adjacent non cancerous tissues. We identified JAZF1 as a direct miR-1275 target. miR-1275 supresses migration and invasion of GC cells in vitro and in vivo, which was restored by JAZF1 overexpression. Moreover, JAZF1 was recognized as a direct regulator of Vimentin. Knocking-down miR-1275 or overexpressing JAZF1 resulted in upregulation of Vimentin but downregulation of E-cadherin. Meanwhile, we validated in 120 GC patients specimens that low miR-1275expression and high JAZF1 mRNA expression levels were closely associated with lymph node metastasis and poor prognosis. The expression of JAZF1 in protein level displayed the correlations with Vimentin but inversely with E-cadherin. Increased miR-1275 expression inhibited GC metastasis by regulating vimentin/E-cadherin via direct suppression of JAZF1expression, suggesting that miR-1275 is a tumour-suppressor miRNA with the potential as a prognostic biomarker or therapeutic target in GC.